NASDAQ:NPCE NeuroPace (NPCE) Stock Price, News & Analysis → Buy Friday, Sell Monday, No Exceptions (From DTI) (Ad) Free NPCE Stock Alerts $13.20 -0.43 (-3.15%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$13.00▼$13.6450-Day Range$12.84▼$17.5052-Week Range$3.80▼$18.15Volume28,526 shsAverage Volume92,907 shsMarket Capitalization$346.90 millionP/E RatioN/ADividend YieldN/APrice Target$15.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get NeuroPace alerts: Email Address NeuroPace MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside18.7% Upside$15.67 Price TargetShort InterestHealthy0.26% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 3 Articles This WeekInsider TradingSelling Shares$41,429 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.14) to ($0.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.04 out of 5 starsMedical Sector246th out of 938 stocksSurgical & Medical Instruments Industry33rd out of 97 stocks 3.4 Analyst's Opinion Consensus RatingNeuroPace has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.67, NeuroPace has a forecasted upside of 18.7% from its current price of $13.20.Amount of Analyst CoverageNeuroPace has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.26% of the float of NeuroPace has been sold short.Short Interest Ratio / Days to CoverNeuroPace has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroPace has recently decreased by 38.57%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeuroPace does not currently pay a dividend.Dividend GrowthNeuroPace does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NPCE. Previous Next 3.9 News and Social Media Coverage News SentimentNeuroPace has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for NeuroPace this week, compared to 1 article on an average week.Search Interest7 people have searched for NPCE on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat Follows11 people have added NeuroPace to their MarketBeat watchlist in the last 30 days. This is an increase of 57% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeuroPace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,429.00 in company stock.Percentage Held by Insiders27.50% of the stock of NeuroPace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.83% of the stock of NeuroPace is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NeuroPace are expected to grow in the coming year, from ($1.14) to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuroPace is -10.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuroPace is -10.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuroPace has a P/B Ratio of 16.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressA lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one About NeuroPace Stock (NASDAQ:NPCE)NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.Read More NPCE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NPCE Stock News HeadlinesMarch 27, 2024 | globenewswire.comNeuroPace to Present at the Needham 23rd Annual Healthcare ConferenceMarch 20, 2024 | americanbankingnews.comNeuroPace, Inc. (NASDAQ:NPCE) Receives Average Recommendation of "Moderate Buy" from BrokeragesMarch 28, 2024 | Crypto Swap Profits (Ad)Grab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 13, 2024 | markets.businessinsider.comThe Latest Analyst Ratings For NeuroPaceMarch 7, 2024 | markets.businessinsider.comNeuroPace Secures Buy Rating from Analyst Mike Kratky Amid Positive Revenue Guidance and Growth DriversMarch 7, 2024 | finance.yahoo.comNeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comNeuroPace Full Year 2023 Earnings: EPS Beats ExpectationsMarch 7, 2024 | seekingalpha.comNeuroPace, Inc. (NPCE) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 6, 2024 | benzinga.comRecap: NeuroPace Q4 EarningsMarch 6, 2024 | msn.comNeuroPace GAAP EPS of -$0.23March 6, 2024 | markets.businessinsider.comNeuroPace Financial Analysis: Hold Rating Maintained Amid Growth and Spending ConcernsMarch 5, 2024 | globenewswire.comNeuroPace Announces Record Full Year 2023 Revenue of $65.4 MillionMarch 5, 2024 | investorplace.comFinancial Freedom Fighters: 3 Stocks to Liberate Your PortfolioFebruary 24, 2024 | msn.comNeuroPace (NPCE) Price Target Increased by 27.95% to 15.01February 22, 2024 | benzinga.comA Glimpse Into The Expert Outlook On NeuroPace Through 4 AnalystsFebruary 22, 2024 | benzinga.comNeuroPace Stock (NASDAQ:NPCE) Earnings Dates and Earning CallsFebruary 15, 2024 | finance.yahoo.comNeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024February 15, 2024 | globenewswire.comNeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024February 8, 2024 | msn.comNeuroPace Announces Chief Legal Officer Irina Ridley’s DepartureFebruary 7, 2024 | uk.finance.yahoo.comNeuroPace Inc Chief Medical Officer Martha Morrell Sells 17,589 SharesFebruary 2, 2024 | finance.yahoo.comNeuroPace Inc Chief Medical Officer Martha Morrell Sells 13,848 SharesJanuary 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: NeuroPace (NPCE), Alignment Healthcare (ALHC) and 10x Genomics (TXG)January 8, 2024 | finanznachrichten.deNeuroPace, Inc: NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business UpdatesDecember 29, 2023 | finance.yahoo.comNeuroPace Inc Chief Medical Officer Martha Morrell Sells 13,402 SharesDecember 28, 2023 | markets.businessinsider.comNeuroPace Stock Poised for Continued Growth: Buy Rating Reaffirmed Amid Operational Successes and Market ExpansionDecember 27, 2023 | realmoney.thestreet.comNeuroPace 'primed for continued outperformance' in 2024, says Lake StreetSee More Headlines Receive NPCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NPCE CUSIPN/A CIK1528287 Webwww.neuropace.com Phone650-237-2700FaxN/AEmployees171Year FoundedN/APrice Target and Rating Average Stock Price Target$15.67 High Stock Price Target$22.00 Low Stock Price Target$9.00 Potential Upside/Downside+18.7%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,960,000.00 Net Margins-50.38% Pretax Margin-50.38% Return on Equity-153.76% Return on Assets-31.73% Debt Debt-to-Equity Ratio2.76 Current Ratio5.71 Quick Ratio5.02 Sales & Book Value Annual Sales$65.42 million Price / Sales5.30 Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book16.71Miscellaneous Outstanding Shares26,280,000Free Float19,056,000Market Cap$346.90 million OptionableOptionable Beta2.16 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Martha J. Morrell (Age 67)Chief Medical Officer Comp: $555.87kMr. Joel D. Becker (Age 56)CEO, President & Director Ms. Rebecca L. Kuhn (Age 63)CFO, VP of Finance & Administration and Assistant Secretary Comp: $440.92kMs. Kelley NicholasVice President of SalesMs. Irene Thomas (Age 55)Vice President of Human Resources Key CompetitorsPulmonxNASDAQ:LUNGFractyl HealthNASDAQ:GUTSTactile Systems TechnologyNASDAQ:TCMDAnika TherapeuticsNASDAQ:ANIKCVRxNASDAQ:CVRXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 27,021 shares on 3/11/2024Ownership: 1.572%Virtu Financial LLCBought 10,764 shares on 2/26/2024Ownership: 0.041%Citadel Advisors LLCBought 24,055 shares on 2/15/2024Ownership: 0.092%Townsquare Capital LLCBought 15,859 shares on 2/15/2024Ownership: 0.060%Barclays PLCBought 3,132 shares on 2/15/2024Ownership: 0.053%View All Insider TransactionsView All Institutional Transactions NPCE Stock Analysis - Frequently Asked Questions Should I buy or sell NeuroPace stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeuroPace in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NPCE shares. View NPCE analyst ratings or view top-rated stocks. What is NeuroPace's stock price target for 2024? 7 brokerages have issued twelve-month target prices for NeuroPace's shares. Their NPCE share price targets range from $9.00 to $22.00. On average, they predict the company's share price to reach $15.67 in the next twelve months. This suggests a possible upside of 18.7% from the stock's current price. View analysts price targets for NPCE or view top-rated stocks among Wall Street analysts. How have NPCE shares performed in 2024? NeuroPace's stock was trading at $10.31 at the beginning of the year. Since then, NPCE shares have increased by 28.0% and is now trading at $13.20. View the best growth stocks for 2024 here. Are investors shorting NeuroPace? NeuroPace saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 30,900 shares, a drop of 38.6% from the February 29th total of 50,300 shares. Based on an average trading volume of 90,700 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.3% of the company's shares are short sold. View NeuroPace's Short Interest. When is NeuroPace's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our NPCE earnings forecast. How were NeuroPace's earnings last quarter? NeuroPace, Inc. (NASDAQ:NPCE) announced its earnings results on Tuesday, March, 5th. The company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.10. The firm earned $18.01 million during the quarter, compared to analyst estimates of $17.74 million. NeuroPace had a negative net margin of 50.38% and a negative trailing twelve-month return on equity of 153.76%. What guidance has NeuroPace issued on next quarter's earnings? NeuroPace issued an update on its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $73.0 million-$77.0 million, compared to the consensus revenue estimate of $74.6 million. When did NeuroPace IPO? NeuroPace (NPCE) raised $85 million in an initial public offering (IPO) on Thursday, April 22nd 2021. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers. Who are NeuroPace's major shareholders? NeuroPace's stock is owned by a number of retail and institutional investors. Top institutional investors include Nantahala Capital Management LLC (4.47%), Kent Lake Capital LLC (2.55%), Vanguard Group Inc. (1.57%), Vanguard Group Inc. (1.57%), Northern Trust Corp (0.13%) and Bridgeway Capital Management LLC (0.13%). Insiders that own company stock include Accelmed Partners Ii LP, Frank M Fischer, Irina Ridley, Ltd Kck, Martha Morrell and Orbimed Advisors Llc. View institutional ownership trends. How do I buy shares of NeuroPace? Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NPCE) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.